Difference between revisions of "How I Treat"
m |
|||
| Line 8: | Line 8: | ||
==[[Acute myeloid leukemia]]== | ==[[Acute myeloid leukemia]]== | ||
*'''2023:''' Biederstädt & Rezvani [https://doi.org/10.1182/blood.2021012411 How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy] [https://pubmed.ncbi.nlm.nih.gov/35512203/ PubMed] | *'''2023:''' Biederstädt & Rezvani [https://doi.org/10.1182/blood.2021012411 How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy] [https://pubmed.ncbi.nlm.nih.gov/35512203/ PubMed] | ||
| + | *'''2021:''' Falini et al. [https://doi.org/10.1182/blood.2020008211 How I diagnose and treat NPM1-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/33171486/ PubMed] | ||
*'''2020:''' DeWolf & Tallman [https://doi.org/10.1182/blood.2019001982 How I treat relapsed or refractory AML] [https://pubmed.ncbi.nlm.nih.gov/32518943/ PubMed] | *'''2020:''' DeWolf & Tallman [https://doi.org/10.1182/blood.2019001982 How I treat relapsed or refractory AML] [https://pubmed.ncbi.nlm.nih.gov/32518943/ PubMed] | ||
*'''2020:''' DiNardo & Wei. [https://doi.org/10.1182/blood.2019001239 How I treat acute myeloid leukemia in the era of new drugs] [https://pubmed.ncbi.nlm.nih.gov/31765470/ PubMed] | *'''2020:''' DiNardo & Wei. [https://doi.org/10.1182/blood.2019001239 How I treat acute myeloid leukemia in the era of new drugs] [https://pubmed.ncbi.nlm.nih.gov/31765470/ PubMed] | ||
Revision as of 01:31, 7 September 2023
The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered high-level expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles.
Articles are presented by condition, in reverse chronological order. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
Note: this page is currently under construction.
Malignant hematology
Acute myeloid leukemia
- 2023: Biederstädt & Rezvani How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy PubMed
- 2021: Falini et al. How I diagnose and treat NPM1-mutated AML PubMed
- 2020: DeWolf & Tallman How I treat relapsed or refractory AML PubMed
- 2020: DiNardo & Wei. How I treat acute myeloid leukemia in the era of new drugs PubMed
- 2016: Ofran et al. How I treat acute myeloid leukemia presenting with preexisting comorbidities PubMed
- 2015: Röllig & Ehninger. How I treat hyperleukocytosis in acute myeloid leukemia PubMed
- 2014: Ossenkoppele & Löwenberg. How I treat the older patient with acute myeloid leukemia PubMed
- 2011: Bakst et al. How I treat extramedullary acute myeloid leukemia PubMed